drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous, genetically modified T lymphocytes engineered to express a chimeric antigen receptor targeting a B-cell surface antigen; CAR signaling (CD3ζ with costimulatory domains) activates T cells to proliferate, release cytokines, and kill malignant B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T lymphocytes are genetically engineered to express a chimeric antigen receptor that binds a B‑cell surface antigen. Antigen engagement triggers CAR signaling (CD3ζ with costimulatory domains), activating the T cells to expand, release cytokines, and kill malignant B cells via cytotoxic mechanisms (e.g., perforin/granzyme‑mediated apoptosis).
drug_name
CT1190B CAR-T cells
nct_id_drug_ref
NCT06734871